My publisher asked me: âOn a scale of 1â10, how sure are you?â [RiskHedge Report] Regarding my conviction level in the $2 EV stock [Chris Wood] By Chris Wood - RiskHedge âOn a scale of 1â10, how sure are you?â my publisher asked me. We were discussing the $2 EV stock that Iâll be releasing new research on tomorrow at 9 am EST. (If you missed my first two essays on this, see [here]( and [here](.) We had already talked about the 2,000% minimum upside in this stock if world governments make its tech mandatory in all new EVs, as I suspect will happen. Now, he wanted to know my conviction level. â8,â I said. âWowâ¦â In investing⦠particularly in microcaps with upside of 1,000% or more⦠8/10 is as good as it gets. If someone ever tells you theyâve got a 10/10 investment, run away. That would be a sure thingâwhich does not exist. A 9/10 is exceedingly rare and only found in bigger stocks. Think: A dominant company with an ironclad monopoly within an industry that is 100% guaranteed to keep growing. Watch Your Inbox Tomorrow
In order to capitalize on the next wave of EV profits, Chris Wood is looking beyond the traditional opportunities of Tesla, Rivian, NIO, and other EV makers... beyond the EV âbatteryâ metals like cobalt, nickel, or lithium... and beyond the âcharging stationâ plays... Because the next big winner in this space will be a tiny stock no oneâs talking about yet... and it currently trades for $1.25 per share. And tomorrow, he is releasing all of his research on this new idea to RiskHedge readers. Be sure to watch your inbox tomorrow morning for all the details. An 8/10 in my world of microcaps is very rare. When you find one, you must seize it. In my career, the only other microcap I wouldâve given an 8/10 was streaming disruptor Magnite (MGNI). It was born a merger that put two perfectly complementary companies together. They formed a digital ad powerhouse that was highly likely to dominate. My readers enjoyed a 422% gain on it. - Hereâs a secret about microcapsâ¦Â In a typical year, dozens of microcaps shoot up 500%â1,000%. Itâs not that hard to find them if you know what youâre doing. The trick is sorting through all the âpretendersâ⦠so you own more of the ones that can realistically shoot up 1,000% and avoid the ones that never get off the ground. I call this âde-risking.â And as Iâll show you, itâs the #1 most important thing about microcap investing. If I could REQUIRE you to read this essay before seeing my new research report on the $2 EV stock tomorrow, I would. Itâs that important. There are five âtraitsâ I look for when de-risking a microcap. When you find the rare one that has all five traits, you may have a big winner. [In my last essay](, I showed you how important it is for a microcap to have a great CEO at the helm. Thatâs trait #1. Here are the other four: - Trait #1: Ironclad patents. Does the company have high-quality patents to protect its technology? In todayâs tech-based economy, small companies need patents. Otherwise, theyâll get ripped off. Remember Groupon (GRPN)? It basically invented the âdaily dealâ space. But it didnât have patents. Less than two years after launching, Groupon had hundreds of competitors. The companyâs stock fell from over $412 in December 2011 to about $8 today. - Trait #2: Thereâs a reason the companyâs stock will go up soon. In analyst speak, this is called a âcatalyst.â Ask: Is there an âeventâ around the corner that will likely propel the stock higher in short order? A catalyst could be a lucrative deal, a merger, a government ruling, or another big announcement, like blowout earnings results. Stocks need a reason to go up. No kidding, right? But youâd be surprised how often investors fall in love with a companyâs breakthrough technology too soon. Theyâll pour money into the stock, then⦠nothing happens. Investing ahead of a catalyst solves that. Consider tiny cancer drug developer Day One Biopharmaceuticals (DAWN). On a Friday this summer, June 10, DAWNâs stock closed at $6.62. That Sunday, the company announced great initial data from a clinical trial in brain cancer patients. The stock jumped 126% the next day to close at $14.96. - Trait #3: Cheapness. Most people donât know how to evaluate how cheap or expensive a microcap is. Microcaps rarely have profits (earnings), so you canât use a P/E ratio. Many microcaps are also just starting to generate revenue. So, you often canât use the popular price-to-sales valuation metric on these stocks either. To figure out if a microcap is cheap, compare the size of the company to the size of the industry itâs going after. Then, estimate how much of that business the company can realistically capture. Ideally, you want a tiny company with a realistic path to seizing a big share of a huge industry. - Trait #4: Government regulators are on the companyâs side. Iâm no fan of regulations in general. Regulation stymies innovation, allows bad businesses to thrive, and rarely accomplishes what itâs supposed to. Now, I will step off my soapbox and say: regulation is a fact of life. And companies that benefit from government regulation can be incredible investments that carry a level of certainty you canât find in their absence. At the extreme, regulators can FORCE the market to buy a companyâs products. Remember when Obamacare was passed in 2010, forcing Americans to buy health insurance? The three biggest health insurance stocks in the USâUnitedHealth Group, Anthem (now Elevance Health), and Cignaâwent on to rise 1,017%, 262%, and 490%. Obamacare propelled health insurance stocks to their best decade in history. In short: The government can effectively force a stock to go up with regulations. My latest âEVâ microcap play has all the traits I look for... Itâs cheap, it has a great CEO, and it has an upcoming âcatalyst.â Also, the government is 100% on its sideâand it has a key patented technology. Iâll tell you all about it tomorrow at 9 am EST. Watch your inbox for an email from me titled: âThe $2 EV Stock I told you aboutâ¦â Chris Wood
Editor, Project 5X Suggested Reading... [Good news: the stock market has a leader again]( [Put Yourself
Out There]( This email was sent to {EMAIL} as part of your subscription to RiskHedge Report.
To opt-out, please visit the [unsubscribe page](. [READ IMPORTANT DISCLOSURES HERE.]( YOUR USE OF THESE MATERIALS IS SUBJECT TO THE TERMS OF THESE DISCLOSURES. Copyright © 2022 RiskHedge. All Rights Reserved
RiskHedge | 1417 Sadler Road, PMB 415 | Fernandina Beach, FL 32034